Daniel Voglewede
Urology · El Paso, TXNPI 1588636633
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Johnson & Johnson at 28.8% of the total. Reporting peaked in 2022 at $46,066 and has fallen 100.0% since, to $14 in 2024. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 528 payments — averaging $236.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$36K
- Bayer$32K
- Myovant Sciences Inc.$19K
- Dendreon Pharmaceuticals LLC$14K
- Astellas Pharma US Inc$8K
- Pfizer$3K
- plus $13K from 27 others
Across 14 payments — averaging $18,204 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$255K
What the payments were for
- Consulting fees$43,08434%
- Speaking & faculty fees$52,93042%
- Travel & lodging$13,47811%
- Food & beverage$14,91012%
- Education$5620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 147 | $36,033 |
| Bayer | 82 | $32,362 |
| Myovant Sciences Inc. | 26 | $18,532 |
| Dendreon Pharmaceuticals LLC | 30 | $13,964 |
| Astellas Pharma US Inc | 73 | $8,047 |
| Pfizer | 21 | $3,272 |
| AstraZeneca | 7 | $3,073 |
| Janssen Research & Development, LLC | 2 | $2,525 |
| Integra GPO, LLC | 2 | $1,698 |
| Janssen Scientific Affairs, LLC | 1 | $1,100 |
| Amgen | 25 | $545 |
| Sun Pharmaceutical Industries Inc. | 17 | $384 |
| Progenics Pharmaceuticals, Inc. | 5 | $384 |
| Verity Pharmaceuticals Inc. | 8 | $303 |
| Axonics, Inc. | 8 | $266 |
| Sumitomo Pharma America, Inc. | 8 | $262 |
| Merck | 10 | $259 |
| Urogen Pharma, Inc. | 3 | $251 |
| Tolmar, Inc. | 6 | $241 |
| Tolmar Pharmaceuticals, Inc. | 8 | $222 |
| Myriad Genetic Laboratories, Inc. | 4 | $202 |
| Boston Scientific | 5 | $193 |
| Novartis | 4 | $190 |
| AbbVie | 8 | $143 |
| Janssen Products, LP | 1 | $85 |
| Foundation Medicine, Inc. | 5 | $75 |
| Telix Pharmaceuticals | 2 | $71 |
| Blue Earth Diagnostics | 4 | $69 |
| Astellas Pharma Global Development | 1 | $65 |
| Calyxo, Inc. | 1 | $55 |
| Caldera Medical, Inc | 1 | $51 |
| Sanofi | 2 | $31 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$124,964 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 225 | $3,225,151 |
| XtandiEnzalutamide | 126 | $1,705,606 |
| NubeqaDarolutamide | 82 | $1,077,160 |
| OrgovyxRelugolix | 90 | $233,113 |
| YonsaAbiraterone Acet,submicronized | 15 | $148,689 |
| Abiraterone Acetate | 38 | $16,845 |
| Methylprednisolone | 15 | $194 |
| Prednisone | 43 | $137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $36,033 | $3,225,151225 claims |
| Astellas Pharma US IncXtandi | $8,047 | $1,705,606126 claims |
| BayerNubeqa | $32,362 | $1,077,16082 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $262 | $233,11390 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,100 | $16,84538 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 urology providers in Texas.
Other urology in El Paso
- Jeffrey SpierEl Paso$77K
- Jesus Herrera-MurilloEl Paso$54K
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
- Arun RaiHouston$920K
- Allen MoreyDallas$914K
- Donald GriffithHouston$732K
- Michael TrotterAustin$590K
- Vitaly MargulisDallas$555K
- Daniel SaltzsteinSan Antonio$547K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.